605199 Stock Overview
Hainan Huluwa Pharmaceutical Group Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Hainan Huluwa Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.63 |
| 52 Week High | CN¥20.09 |
| 52 Week Low | CN¥9.09 |
| Beta | 0.81 |
| 11 Month Change | -7.34% |
| 3 Month Change | 33.51% |
| 1 Year Change | -31.73% |
| 33 Year Change | -49.15% |
| 5 Year Change | n/a |
| Change since IPO | 69.08% |
Recent News & Updates
We Think That There Are Issues Underlying Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Earnings
Nov 06
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Recent updates
We Think That There Are Issues Underlying Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Earnings
Nov 06Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Shareholder Returns
| 605199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.5% | 1.0% | -0.9% |
| 1Y | -31.7% | -4.8% | 5.4% |
Return vs Industry: 605199 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 605199 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 605199 volatility | |
|---|---|
| 605199 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 605199 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 605199's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,468 | Jinping Liu | www.huluwayaoye.com |
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other therapeutic in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 605199 fundamental statistics | |
|---|---|
| Market cap | CN¥5.29b |
| Earnings (TTM) | CN¥112.88m |
| Revenue (TTM) | CN¥1.82b |
44.8x
P/E Ratio2.8x
P/S RatioIs 605199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605199 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.82b |
| Cost of Revenue | CN¥830.01m |
| Gross Profit | CN¥990.98m |
| Other Expenses | CN¥878.10m |
| Earnings | CN¥112.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 54.42% |
| Net Profit Margin | 6.20% |
| Debt/Equity Ratio | 110.4% |
How did 605199 perform over the long term?
See historical performance and comparison